搜索结果 | 泌尿系统常见疾病循证医学证据

证据分类

搜索结果

共搜索到9条与Transitional Cell/drug therapy有关的结果

Systematic review of reported association studies of monogenic genes and bladder cancer risk and confirmation analysis in a large population cohort

 2023 年发布于 BJUI Compass 21 卷第 1 期

Mian A. Wei J. Shi Z. Rifkin A. S. Zheng S. L. Glaser A. P. Kearns J. T. Helfand B. T. Xu J.

Humans Immune Checkpoint Inhibitors/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/drug therapy Proportional Hazards Models Eastern Cooperative Oncology Group Immune checkpoint inhibitor Performance status Urothelial carcinoma
文献简介 原文链接
Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: A systematic review and network meta-analysis

 2023 年发布于 Cancer Med 27 卷第 4 期

Wu J. Gao Y. Xiong Z. Xiao X. Yang J. Yang X. Huang Y.

Humans *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/pathology *Urologic Neoplasms/drug therapy/pathology Antibodies Monoclonal/adverse effects
文献简介 原文链接
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis

 2022 年发布于 Urol Oncol 46 卷第 2 期

van Hattum J. W. de Ruiter B. Oddens J. R. de Reijke T. M. Wilmink J. W. Molenaar R. J.

*Carcinoma Transitional Cell/drug therapy Humans Organoids Precision Medicine *Urinary Bladder Neoplasms/drug therapy Urothelium/pathology Metastases Personalized medicine Stem cells Transurethral resection
文献简介 原文链接
Decreased Preoperative Serum AGR as a Diagnostic Marker of Poor Prognosis after Radical Surgery of Upper Urinary Tract and Bladder Cancers from a Pooled Analysis of 9,002 Patients

 2022 年发布于 World J Urol 32 卷第 9 期

Wang X. Yang G. Chai Y. Li Z. Che X. Wang Y. Yang L. Zhou Z.

Humans Carboplatin/therapeutic use *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms Carboplatin Cisplatin Immune checkpoint inhibitors Platinum-based chemotherapy Urothelial carcinoma
文献简介 原文链接
The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis

 2022 年发布于 Int J Urol 86 卷第 1 期

Zhou W. Liu J. Mao D. Hu C. Gao D.

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.
文献简介 原文链接
Can a reresection be avoided after initial en bloc resection for high-risk nonmuscle invasive bladder cancer? A systematic review and meta-analysis

 2022 年发布于 Irish Journal of Medical Science 36 卷第 6 期

Xu J. Xu Z. Yin H. Zang J.

*Antineoplastic Agents/adverse effects *Carcinoma Transitional Cell/drug therapy Humans Mutation Receptor ErbB-2 Trastuzumab/adverse effects *Urinary Bladder Neoplasms/drug therapy Erbb2 Her2 Metastatic bladder cancer Metastatic urothelial cancer Targeted treatment
文献简介 原文链接
Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: A systematic review and meta-analysis

 2022 年发布于 Eur Urol 17 卷第 4 期

Sharma G. Sharma A. Krishna M. Ahluwalia P. Gautam G.

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy
文献简介 原文链接
[Guidelines from the cancer (CC-AFU) and infection disease (CI-AFU) committees of the French Association of Urology for the management of adverse events and complications of BCG]

 2022 年发布于 Prog Urol 32 卷第 3 期

Audenet F. Sotto A. Roumiguié M. Allory Y. Andrejak C. Leon P. Loriot Y. Masson-Lecomte A. Pradère B. Seisen T. Traxer O. Xylinas E. Bruyère F. Roupret M. Saint F. Neuzillet Y.

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma
文献简介 原文链接
Concomitant endoscopic surgery for bladder tumors and prostatic obstruction; safely hitting two birds with one stone? A systematic review and meta-analysis

 2022 年发布于 Current Problems in Cancer 61 卷第 22 期

Savvides E. Pyrgidis N. Laggas G. Symeonidis E. Dimitriadis G. Sountoulides P.

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma
文献简介 原文链接

 2023 年 发布于 BJUI Compass 21 卷 第 1 期

Mian A. Wei J. Shi Z. Rifkin A. S. Zheng S. L. Glaser A. P. Kearns J. T. Helfand B. T. Xu J.

 2023 年 发布于 Cancer Med 27 卷 第 4 期

Wu J. Gao Y. Xiong Z. Xiao X. Yang J. Yang X. Huang Y.

 2022 年 发布于 Urol Oncol 46 卷 第 2 期

van Hattum J. W. de Ruiter B. Oddens J. R. de Reijke T. M. Wilmink J. W. Molenaar R. J.

 2022 年 发布于 World J Urol 32 卷 第 9 期

Wang X. Yang G. Chai Y. Li Z. Che X. Wang Y. Yang L. Zhou Z.

 2022 年 发布于 Int J Urol 86 卷 第 1 期

Zhou W. Liu J. Mao D. Hu C. Gao D.

 2022 年 发布于 Irish Journal of Medical Science 36 卷 第 6 期

Xu J. Xu Z. Yin H. Zang J.

 2022 年 发布于 Eur Urol 17 卷 第 4 期

Sharma G. Sharma A. Krishna M. Ahluwalia P. Gautam G.

 2022 年 发布于 Prog Urol 32 卷 第 3 期

Audenet F. Sotto A. Roumiguié M. Allory Y. Andrejak C. Leon P. Loriot Y. Masson-Lecomte A. Pradère B. Seisen T. Traxer O. Xylinas E. Bruyère F. Roupret M. Saint F. Neuzillet Y.

 2022 年 发布于 Current Problems in Cancer 61 卷 第 22 期

Savvides E. Pyrgidis N. Laggas G. Symeonidis E. Dimitriadis G. Sountoulides P.

 2023 年发布于 BJUI Compass 21 卷第 1 期

 2023 年发布于 Cancer Med 27 卷第 4 期

 2022 年发布于 Urol Oncol 46 卷第 2 期

 2022 年发布于 World J Urol 32 卷第 9 期

 2022 年发布于 Int J Urol 86 卷第 1 期

 2022 年发布于 Irish Journal of Medical Science 36 卷第 6 期

 2022 年发布于 Eur Urol 17 卷第 4 期

 2022 年发布于 Prog Urol 32 卷第 3 期

 2022 年发布于 Current Problems in Cancer 61 卷第 22 期